Biostatistics and Data Management Platform

Our expert team brings together experts in the field of biostatistics and data management.

The Biostatistics and Data Management Platform utilises innovative statistical techniques to enable translation of BRC projects.  This encompasses advice on study design and data collection through to innovative statistical modelling to ensure that all research data are captured appropriately for analyses. The Platform supports the development, hosting and maintenance of electronic Case Report Forms (eCRF), essential for capture of clinical data as well as databases for service evaluation, randomised clinical trials, patient online data entry and disease registers. The platform provides statistics training courses and consultancy services to clinical researchers.

Research impact

• The platform developed, hosted and maintains the database for data capture for the Psoprotect registry which collects clinician and patient-reported data on cases of COVID-19 and the impact on psoriasis and related immune-mediated inflammatory diseases. (Mahil SK, et al. J Eur Acad Dermatol Venereol. 2021; Satveer K Mahil, et al. J Allergy Clin Immunol. 2021 Jan).
• The platform provided the adaptive study design and statistical analysis for the EMPIRIKAL phase 1 clinical trial in evaluating the efficacy of Mirococept in reducing delayed graft function (DGF) in deceased donor renal transplantation. The study found the ex vivo administration of Mirococept to be a safe and feasible approach to treat DGF in deceased donor kidney transplantation (Kassimatis T, et al, Am J Transplant 2021; 21: 1012-1026).
• The platform supports the study with clinical data management and data reporting for the AStar multicentre clinical registry of paediatric and adult patients on systemic immune-modulatory therapies. The study aimed to understand and optimise prescribing practices. (F.M.Vermeulen, et al. Br j Dermatol. 2020 Dec).
• The platform provided biostatistics support, including study powering and statistical analysis, to a study investigating faecal microbiota transplantation (FMT) for the treatment of cirrhosis (the PROFIT trial). The study showed that FMT is safe and feasible for the treatment of cirrhosis (Woodhouse, C., et al, J. Hepatology, 2020 (73): 557-558).
• The platform undertook the biostatical data analysis for the Enquiring About Tolerance trial which investigated the early introduction of allergenic foods to new-borns to prevent the development food allergies (the EAT trial). The study showed efficacy in preventing food allergies in specific groups of infants at high risk of developing food allergy (Perkin, M., et al J Allergy Clin Immunol. 2019, 144(6): 1606-1614).